Direkt zum Inhalt
Merck

A2736

Sigma-Aldrich

Anastrozol

≥98% (HPLC)

Synonym(e):

2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1, 3-Phenylene]bis(2-methyl-propiononitrile, Arimidex, ICI-D1033, ZD1033, a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C17H19N5
CAS-Nummer:
Molekulargewicht:
293.37
UNSPSC-Code:
51111800
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

solid

Löslichkeit

DMSO: 40 mg/mL

Ersteller

AstraZeneca

Lagertemp.

room temp

InChI

1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3

InChIKey

YBBLVLTVTVSKRW-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Anastrozole (aromatase inhibitor) has been used:
  • as a positive control in DNA fragmentation (ladder) assay
  • to investigate its effects along with extra virgin olive oil and its major fatty acid component (omega-9 OA) in estrogen receptor positive mammary adenocarcinoma cells
  • to study its effects on viability, cell proliferation and apoptosis in Glioblastoma multiforme model in vivo

Biochem./physiol. Wirkung

Anastrozole, which contains a triazole functional group, reversibly binds to the cytochrome P-450 component of aromatase. Binding interferes with the catalytic properties of aromatase, which results in inhibition of estrogen synthesis.
The aromatase enzyme converts adrenal androgens to estrogen; this enzymatic activity is the primary source of estrogen production in postmenopausal women. One treatment for estrogen receptor-positive breast cancer in postmenopausal women is through inhibition of aromatase. Anastrozole is a nonsteroidal, benzyl-triazole derivative that inhibits aromatase through competitive inhibition and is used to treat estrogen receptor-positive breast cancer. This compound is considered a third-generation, Type II aromatase inhibitor because it is more selective and less effective (if at all) on other steroidal hormones than first and second generation inhibitors.

Leistungsmerkmale und Vorteile

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Health hazardExclamation mark

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Acute Tox. 4 Oral - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Novel acylated steroidal glycosides from Caralluma tuberculata induce caspase-dependent apoptosis in cancer cells
Waheed A, et al.
Journal of Ethnopharmacology, 137(3), 1189-1196 (2011)
Yanyan Hong et al.
Steroids, 76(8), 802-806 (2011-03-23)
Aromatase is the rate-limiting enzyme in estrogen biosynthesis. As a cytochrome P450, it utilizes electrons from NADPH-cytochrome P450 reductase (CPR) to produce estrogen from androgen. Estrogen is a key factor in the promotion of hormone-dependent breast cancer growth. Aromatase inhibitors
P Dubsky et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(3), 640-647 (2012-10-05)
In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance
F Boccardo et al.
European journal of cancer (Oxford, England : 1990), 49(7), 1546-1554 (2013-02-19)
The Italian Tamoxifen Anastrozole (ITA) trial investigated the efficacy of switching to anastrozole for women who were already on adjuvant tamoxifen since 2-3years. Relapse-free survival (RFS) was the primary end-point; event-free survival (EFS), overall survival (OS) and safety were secondary
P I Petkov et al.
SAR and QSAR in environmental research, 20(7-8), 657-678 (2009-12-22)
Cytochrome P450 aromatase is a key steroidogenic enzyme that converts androgens to estrogens in vertebrates. There is much interest in aromatase inhibitors (AIs) both because of their use as pharmaceuticals in the treatment of estrogen-sensitive breast cancers, and because a

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.